A suggested positive control for Western blot is HUVEC cells; suggested positive control for IHC is human breast carcinoma.
ATF-2 is a member of the group of bZip transcription factors. Heterodimer formation between members of the bZip group is common and is believed to add diversity to the cis-acting elements at which binding of the dimers is directed. Specifically, ATF-2 may dimerize with c-Jun, as occurs in response to E1a, and in so doing shift the binding preference of c-Jun toward ATF/CRE sites. Deletion analysis has indicated that the N-terminal region of ATF-2 containing threonine at residues 69 and 71 are essential for this purpose. These threonine residues are phosphorylated by JNK/SAPK for transcriptional activation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Activating 2; Activating transcription factor 2; activating transcription factor 2 splice variant ATF2-var2; ATF2; cAMP response element binding protein CRE- BP1; cAMP response element-binding protein CRE-BP1; cAMP responsive element binding protein 2, formerly; cAMP-dependent transcription factor ATF-2; CREB-2; CREB2; CREBP1; Cyclic AMP-dependent transcription factor ATF-2; Cyclic AMP-responsive element-binding protein 2; Cyclic-AMP-dependent ATF-2; HB16; Histone acetyltransferase ATF2; MXBP protein
Gene Aliases: Atf-2; ATF2; CRE-BP; CRE-BP1; CREB-2; CREB2; CREBP1; D130078H02Rik; D18875; HB16; mXBP; Tg(Gzma-Klra1)7Wum; TREB7